  {
    "id": 13113062,
    "author": "Shanthi Rexaline",
    "created": "Sun, 10 Feb 2019 18:37:42 -0400",
    "updated": "Tue, 12 Feb 2019 10:32:14 -0400",
    "title": "The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",
    "teaser": "Biotech stocks held steady in the recent week as  earnings  from the sector continue to trickle in. The week also saw presentations of clinical trial readouts at a couple of conferences.",
    "body": "<p>Biotech stocks held steady in the recent week as <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/19/02/13102496/analysts-focus-on-gileads-late-stage-data-readouts-foll\"> earnings </a> from the sector continue to trickle in. The week also saw presentations of clinical trial readouts at a couple of conferences.</p>\n<p>The following are key catalysts that could move biotech stocks in the upcoming week.</p>\n<h3>Conferences</h3>\n<ul>\n<li>International Conference on Biomarkers and Cancer Targets: Feb. 14-15 in Dubai, UAE</li>\n<li>18th Global Ophthalmology, Optometry and Glaucoma Conference: Feb. 14-15, in Dubai</li>\n<li>ASCO Genitourinary Cancers Symposium: Feb. 14-16, in San Francisco, California</li>\n</ul>\n<h3>PDUFA Dates</h3>\n<p><strong>MOTIF BIO PLC/S ADR </strong>(NASDAQ: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/mtfb#NASDAQ\">MTFB</a>)&#39;s NDA for iclaprim to treat acute bacterial skin and skin structure infections awaits FDA clearance. The PDUFA date for the NDA is set for Wednesday, Feb. 13.</p>\n<p>The FDA is set to rule on <strong>Bausch Health Companies Inc </strong>(NYSE: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/bhc#NYSE\">BHC</a>)&#39;s NDA for Duobrii, which is being evaluated for&nbsp;plaque psoriasis, on Friday, Feb. 15. The application was handed&nbsp;a CRL in June 2018 after which the company made a resubmission in August.&nbsp;</p>\n<p><strong>Merck &amp; Co., Inc. </strong>(NYSE: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/mrk#NYSE\">MRK</a>) awaits the FDA verdict on its sBLA for Keytruda as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma. The due date&nbsp;is Saturday, Feb. 16.</p>\n<p><strong>Adcom Meeting </strong></p>\n<p>A Feb. 12 joint meeting of FDA&#39;s Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee is set to deliberate on <strong>Johnson &amp; Johnson </strong>(NYSE: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/jnj#NYSE\">JNJ</a>) unit Janssen&#39;s NDA for an esketamine 28 mg single-use nasal spray device for&nbsp;treatment-resistant depression.</p>\n<p><em>See Also: <a href=\"https://www.benzinga.com/general/biotech/19/02/13041771/attention-biotech-investors-mark-your-calendar-for-these-february-pdu\">Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates</a></em></p>\n<h3>Clinical Trial Results</h3>\n<p><strong>ASCO GU Cancers Symposium Presentations </strong></p>\n<p><strong>Veru Inc </strong>(NASDAQ: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/veru#NASDAQ\">VERU</a>) is scheduled to make a poster presentation of Phase 2 data on its hot flashes treatment candidate zuclomiphene citrate&nbsp;Feb. 14.</p>\n<p><strong>Pfizer Inc. </strong>(NYSE: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/pfe#NYSE\">PFE</a>) will present Feb. 14 a poster on Phase 3 data for Xtandi, its metastatic hormone-sensitive prostate cancer candidate.</p>\n<p><a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/11/12740354/merck-is-up-40-in-2018-whats-driving-the-rally\">Merck </a> and Pfizer are due to present Feb.16 with Phase 3 data on&nbsp;Keytruda in combination with Inlyta for treating renal cell carcinoma.</p>\n<p><strong>AVEO Pharmaceuticals, Inc. </strong>(NASDAQ: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/aveo#NASDAQ\">AVEO</a>) is set to present Feb.16 an abstract of Phase 3 data for tivozanib, which is being evaluated as a third-line treatment for patients with renal cell carcinoma.</p>\n<p><strong>Calithera Biosciences Inc </strong>(NASDAQ: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/cala#NASDAQ\">CALA</a>) is due to make a poster presentation Feb. 16 on the Phase 2 study of CB-839 and cabozantinib for renal cell carcinoma.</p>\n<h3>Earnings</h3>\n<h3>Tuesday, Feb. 12</h3>\n<li><strong>Exelixis, Inc. </strong>(NASDAQ: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/exel#NASDAQ\">EXEL</a>) (after the market close)</li>\n\n<h3>Wednesday, Feb. 13</h3>\n<ul>\n<li><strong>Ironwood Pharmaceuticals, Inc. </strong>(NASDAQ: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/irwd#NASDAQ\">IRWD</a>) (before the market open)</li>\n<li><strong>Natus Medical Inc </strong>(NASDAQ: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/baby#NASDAQ\">BABY</a>) (before the market open)</li>\n<li><strong>Vanda Pharmaceuticals Inc. </strong>(NASDAQ: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/vnda#NASDAQ\">VNDA</a>) (after the market close)</li>\n</ul>\n<h3>Thursday, Feb. 14</h3>\n<ul>\n<li><strong>Agios Pharmaceuticals Inc </strong>(NASDAQ: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/agio#NASDAQ\">AGIO</a>) (before the market open)</li>\n<li><strong>Incyte Corporation </strong>(NASDAQ: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/incy#NASDAQ\">INCY</a>) (before the market open)</li>\n<li><strong>Zoetis Inc </strong>(NYSE: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/zts#NYSE\">ZTS</a>) (before the market open)</li>\n<li><strong>Prothena Corporation PLC </strong>(NASDAQ: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/prta#NASDAQ\">PRTA</a>) (after the market close)</li>\n<li><strong>Acorda Therapeutics Inc </strong>(NASDAQ: <a class=\"ticker\" href=\"https://www.benzinga.com/stock/acor#NASDAQ\">ACOR</a>) (after the market close)</li>\n</ul>\n<h3>IPOs</h3>\n<p><strong>Anchiano Therapeutics</strong> is set to offer 2.4 million shares in an IPO priced at $14.55 each. The biotech that develops therapies for early stage bladder cancer seeks to list its shares on the Nasdaq under the ticker symbol ANCN.</p>\n<p><strong>Stealth Biotherapeutics</strong>, which focuses on therapies for mitochondrial dysfunction, will offer 6.2 million shares priced between $12 and $14. The shares are to be listed on the Nasdaq under the ticker symbol MITO.</p>\n<p><strong>TCR2 Therapeutics</strong> will offer 5 million shares in an IPO&nbsp;with an estimated price range of $14-$16. This immuno-oncology biotech is looking to list its shares on the Nasdaq under the ticker symbol TCRR.</p>\n",
    "url": "https://www.benzinga.com/general/biotech/19/02/13113062/the-week-ahead-in-biotech-conferences-pdufa-dates-and-clinical-trials",
    "image": [
      {
        "size": "thumb",
        "url": "https://cdn1.benzinga.com/files/imagecache/250x187xUP/images/story/2012/medic-563423_1920_349.jpg"
      },
      {
        "size": "small",
        "url": "https://cdn1.benzinga.com/files/imagecache/1024x768xUP/images/story/2012/medic-563423_1920_349.jpg"
      },
      {
        "size": "large",
        "url": "https://cdn1.benzinga.com/files/imagecache/2048x1536xUP/images/story/2012/medic-563423_1920_349.jpg"
      }
    ],
    "channels": [
      {
        "name": "Biotech"
      },
      {
        "name": "Earnings"
      },
      {
        "name": "News"
      },
      {
        "name": "Previews"
      },
      {
        "name": "FDA"
      },
      {
        "name": "Top Stories"
      },
      {
        "name": "Trading Ideas"
      }
    ],
    "stocks": [
      {
        "name": "ACOR"
      },
      {
        "name": "AGIO"
      },
      {
        "name": "AVEO"
      },
      {
        "name": "BABY"
      },
      {
        "name": "BHC"
      },
      {
        "name": "CALA"
      },
      {
        "name": "EXEL"
      },
      {
        "name": "IBB"
      },
      {
        "name": "INCY"
      },
      {
        "name": "IRWD"
      },
      {
        "name": "JNJ"
      },
      {
        "name": "MRK"
      },
      {
        "name": "MTFB"
      },
      {
        "name": "PFE"
      },
      {
        "name": "PRTA"
      },
      {
        "name": "VERU"
      },
      {
        "name": "VNDA"
      },
      {
        "name": "XBI"
      },
      {
        "name": "ZTS"
      }
    ],
    "tags": []
  }